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ABSTRACT
Myriocin is an antibiotic derived from Mycelia sterilia, and is a potent inhibitor of serine palmitoyltrans-
ferase, the enzyme involved in the first step of sphingosine synthesis. Myriocin, inhibiting ceramide
synthesis, has a great potential for treatment of diseases characterized by high ceramide levels in
affected tissues, such as retinitis pigmentosa (RP). Drug delivery to the retina is a challenging task,
which is generally by-passed through intravitreal injection, that represents a risky invasive procedure.
We, therefore, developed and characterized an ophthalmic topical nanotechnological formulation
based on a nanostructured lipid carrier (NLC) and containing myriocin. The ocular distribution of myr-
iocin in the back of the eye was assessed both in rabbits and mice using LC-MS/MS. Moreover, rabbit
retinal sphingolipid and ceramides levels, after myriocin-NLC (Myr-NLC) eye drops treatment, were
assessed. The results demonstrated that Myr-NLC formulation is well tolerated and provided effective
levels of myriocin in the back of the eye both in rabbits and mice. We found that Myr-NLC eye drops
treatment was able to significantly decrease retinal sphingolipid levels. In conclusion, these data sug-
gest that the Myr-NLC ophthalmic formulation is suitable for pharmaceutical development and war-
rants further clinical evaluation of this eye drops for the treatment of RP.
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Introduction
Myriocin, a natural compound with immunosuppressive
activity, worked as a template compound for the develop-
ment of fingolimod, a drug approved for the treatment of
multiple sclerosis. Fingolimod retained the immunosuppres-
sant activity of myriocin but not the inhibitory activity on
serine palmitoyltransferase (Zecri, 2016), the enzyme involved
in the first step of sphingolipids (i.e. ceramides) synthesis.
The dysregulation of ceramide biosynthesis in retinitis pig-
mentosa (RP), a genetically heterogeneous disorder causing
photoreceptor degeneration and blindness, was hypothe-
sized for the first time in 2004. The mutation of ceramide
kinase like gene (CERKL) was associated with autosomal
recessive RP (RP26) (Tuson et al., 2004). The endogenous
substrate of CERKL has not been identified yet. CERKL lipid
kinase activity has not been confirmed as well, but the role
of CERKL in the regulation of the retinal sphingolipid metab-
olism was proven by Garanto et al. (2013). The sphingolipid
metabolism was found to be altered in the retinal degener-
ation 10 (rd10) mouse model of RP (Strettoi et al., 2010).
Particularly, the levels of pro-apoptotic ceramide were found
to be higher in the retina of rd10 mice compared to con-
trol mice.
It has been demonstrated that topical ocular administra-
tion of myriocin preserves photoreceptor structure and func-
tion in a mouse model of retinitis pigmentosa (Strettoi et al.,
2010), assessed by electroretinography (ERG) as well as by
morphological and biochemical tests (Piano et al., 2013).
Moreover, the rationale for using ceramide-synthesis inhibi-
tors to reduce photoreceptor apoptosis in retinitis pigmen-
tosa has also been reviewed (Guadagni et al., 2015). Myriocin
nanotechnological eye drops formulations, myriocin-loaded
solid lipid nanoparticles (Myr-SLN), were also tested in animal
model of RP, along with myriocin intravitreal injection in
rd10 mice (Strettoi et al., 2010; Piano et al., 2013).
Nanotechnological drug delivery systems are characterized
by several advantages, such as noninvasive administration,
biocompatibility, biodegradability, bio-adhesive properties,
high encapsulation efficiency and loading capacity, good bio-
availability for poorly soluble drugs, good targeting and con-
trolled release (Ameeduzzafar et al., 2018; Imam et al., 2018;
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Baig et al., 2016). These characteristics led to the fruitful
exploitation of nanotechnology for ocular drug delivery.
Nanostructured lipid carrier (NLC) formulations, a second
generation of lipid nanoparticles, have shown better charac-
teristics compared to SLN (Battaglia and Gallarate, 2012;
Araujo et al., 2011; Puglia et al., 2015; Puglia et al., 2018). In
fact, SLN are characterized by some drawbacks, such as drug
expulsion during storage (Battaglia et al., 2016) and lower
drug loading, compared to NLC (M€uller et al., 2002). The NLC
are composed by blends of lipids with different melting tem-
peratures, but solid at body temperature. Therefore, during
the cooling of the lipid mixture, the liquid (oily) fraction
causes nano-structural imperfections (nano-compartments of
oil) in lipid nanoparticles. These oil compartments in the
solid matrix increase the drug solubility, thus augmenting
the total drug loading capacity of NLC, compared to SLN
(Puglia et al., 2018; M€uller et al., 2002). The aim of the pre-
sent study was the preparation and characterization of a
novel ophthalmic formulation based on NLC able to deliver
myriocin to the back of the eye after topical administration.
Furthermore, we assessed retinal sphingolipid levels after
Myr-NLC eye drops treatment.
Materials and methods
Materials
Myriocin (Myr) from Mycelia sterilia 98% (HPLC) powder
was purchased from Sigma-Aldrich (Milan, Italy); 14-hydroxy-
myriocin was prepared in our laboratory by chemical reduc-
tion of the carbonyl group, purified and characterized by
mass spectrometry. Sphingolipids standards were purchased
by Avanti Polar Lipids (Alabaster, USA). GelucireVR 44/14
(lauroyl polyoxyl-32 glycerides) was donated by Gattefosse
(France). Mygliol 812VR (triglyceride capric/caprylic acids) was
purchased from Farmalabor (Italy). Tween 80 and benzalko-
nium chloride were purchased from Sigma-Aldrich
(Milan, Italy).
Methanol (MeOH), acetonitrile, ammonium formate, acetic
acid, potassium hydroxide (KOH) and formic acid (all of ana-
lytical grade) were supplied by Merck (Darmstadt, Germany).
Water was MilliQ grade.
Methods
Preparation of blank NLC
Unloaded NLC (NLC0) was prepared using an adapted melt-
emulsification and ultrasonication technique (Silva et al.,
2011). Firstly, the aqueous phase was prepared at room tem-
perature adding to distilled water the surfactant Tween 80
(2.5% w/v) and the preservative benzalkonium chloride of
(0.05% w/v), then the aqueous phase was stored at 4 C. The
lipid matrix was prepared by heating Gelucire 44/14 (10% w/
v) and Mygliol 812 (5% w/v) to 75 C (according to our pre-
formulation studies, data not shown). The aqueous phase,
heated to the same temperature of the lipid matrix, was
slowly added to the melted lipid matrix. Then the mixture
was continuously stirred at 500 rpm. A pre-emulsion was
thus obtained, cooled and then sonicated using a probe son-
icator (S-250A analog Sonifier; Branson), set at 70% ampli-
tude for 15min, in order to form a nano-emulsion. After
sonication, the NLC formulations were stored at 4 C. The
characterization analysis of the NLCs was carried out 24 h
after preparation, in order to reach system equilibration.
Preparation of myriocin-loaded NLCs
Myriocin loaded NLC (Myr-NLC) were prepared with the
same technique of unloaded NLC. Myriocin (1 or 2mg/ml,
respectively for batches NLC1 and NLC2) was added to the
lipid matrix, heated at 75 C. The aqueous phase, heated at
75 C, was then dropped into the lipid matrix, under continu-
ous stirring. Then, the pre-emulsion was immediately cooled
and sonicated for 15min. Finally, formulations were stored at
4 C and analyzed 24 h after preparation.
Nanoparticle characterization
Mean particle size (Z-Ave), polydispersity index (PDI), Zeta
potential (ZP), physical appearance, pH value and physical
stability were determined for unloaded (NLC0) and Myr-NLC
(NLC1, NLC2) formulations. The mean size and PDI were
determined by photocorrelation spectroscopy (dynamic light
scattering) with the instrument NanoSizer ZS90 (Malvern
Instruments, UK). Samples were ten-fold diluted with distilled
water before mean size and PDI analyses. Values are
reported as mean± SD from 90 measurements (three sets
of 10 measurements in triplicate). The ZP values were
calculated with the software of NanoSizer ZS90 (Malvern
Instruments, UK); using the Smoluchowski equation and
including the average values of electrophoretic
nanoparticle mobility. ZP values are reported as the mean of
three sets of 100 measurements. The pH values were
measured with a pH-meter XS INSTRUMENTS mod pH 510
(Carpi Monza - Italy).
Nanoparticle stability studies
Stability of NLC formulations upon storage was evaluated.
NLC were stored in closed glass vials at 4 C; size and phys-
ical appearance were evaluated 1, 3, and 6months after NLC
preparation. Data of stored NLC were recorded and com-
pared with NLC preparation at time zero.
Formulation sterilization
NLC sterilization was carried out with several sterilization fil-
ters. Evaluation of NLC physical characteristics was carried
out and compared to pre-sterilized NLC. To choose the most
suitable filter, sterilization steps were carried out at first on
unloaded NLC with different syringe filters (0.22mm mem-
brane mesh): (i) 4-mm disposable filter device with 0.2mm
nylon (NYL) membrane (Polypropylene housing) (Whatman);
(ii) 25-mm disposable filter device with 0.2mm polyethersul-
fone (PES) membrane (GD/X) (Whatman); (iii) 13-mm dispos-
able filter with 0.2 mm polytetrafluorethylene (PTFE,
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Hydrophilic FluoroporeVR ) membrane (MillexVR -LG).
Nanoparticle size was evaluated immediately after NLC prep-
aration, then NLC formulations were sterilized and re-ana-
lyzed, to evaluate preservation of characteristic pre-filtered
NLC properties.
Myriocin extraction procedure from biological samples
Myriocin was extracted as described by Campisi et al. with
some modifications (Campisi et al., 2017). Weighted retinal
samples were pretreated with 100 ml of PBSþ 0.1% protease
inhibitor, samples were then homogenized in the TissueLyser
(Qiagen, Hilden, Germany) for 3min at 50 oscillations/s.
Rabbit retina homogenate (about 50mg) was aliquoted, 70 ml
and 30 ml for extraction of myriocin and sphingolipids,
respectively. The homogenate of the mouse retina (about
5mg) was used entirely for myriocin determination. The
internal standard (50mL, 14-OH myriocin 0.1 mg/ml) and
900ml of distilled water were added to the tissue homogen-
ate, then sonicated for 30min. After centrifugation for 5min
at 10000 rpm, the supernatant was loaded on Strata X 30mg
cartridges (Phenomenex, CA, USA) connected to Supelco
Visiprep Dil solid phase extraction (SPE) machine. Cartridges
were previously conditioned with methanol (MeOH, 1ml)
and distilled water (1ml). The cartridges were rinsed with
15% MeOH (1ml), and then with 50% MeOH. Cartridges
were dried under vacuum for 5min, to remove excess water.
The retained extracted sample was then eluted with MeOH/
acetonitrile (1:1) þ 0.1% formic acid (1ml). The eluate was
subjected to a gentle nitrogen stream, until dryness. Finally,
the product of SPE purification was re-dissolved into 150 ml
acetonitrile/water (1:1). Then, 10 mL of the sample were
injected into LC-MS/MS instrumentation for quantitative ana-
lysis. Rabbit’s vitreous was filtered through a nylon filtering
membrane (NY, mesh diameter 0.45 mm). The internal stand-
ard was added to purified samples (50mL, 14-OH myriocin
0.1mg/mL), then 10 mL of sample were directly injected into
the LC-MS/MS.
Sphingolipid extraction procedure from
biological samples
The sphingolipid extraction was modified compared to the
protocol previously published by Dalmau et al. (2015). Rabbit
retinal homogenate (30 mL) was diluted with 70 mL of PBS þ
0.1% protease inhibitor. Proteins were quantified with the
Bradford method. The internal standard was added to the
purified sample (10 ml, Cer C12 20mM) along with a mixture
of MeOH/chloroform (2:1, v/v), then sonicated for 30min.
Samples were then incubated overnight in an oscillator bath
at 48 C. Once at room temperature, 75 ll of 1M KOH in
MeOH were added to the samples, then subjected to 2 h
incubation at 37 C. The pH was adjusted at 7.0 by adding
75ll 1M acetic acid in MeOH. After evaporation with a gen-
tle stream of nitrogen, samples were dissolved in 150ll of
MeOH and then centrifuged for 10min at 13000 rpm. After
this, 10 mL of purified samples were directly injected into the
LC-MS/MS instrument for quantitative analysis.
LC-MS/MS instrument and analysis parameters
The analytical system consisted of a UPLC Dionex 3000
UltiMate (Thermo Fisher Scientific, USA) connected to an
ABSciex 3200 QTRAP with electrospray ionization
TurboIonSprayTM source (AB Sciex S.r.l., Milano, Italy). The LC-
MS/MS analysis of myriocin was carried out according to
Campisi et al. (2017), while the sphingolipids analysis was
carried out as described by Merrill et al. (2005).
Technical details are thoroughly explained in the
Supplementary material.
Analytical performance of myriocin and
sphingolipids analysis
For myriocin analysis, the calibration curves were built by
adding up to 200 ng/vial to the blank matrix. Linearity was
observed in the whole range of the calibration curve
(y¼ 0.8185x 0.0455, R2 = 0.9991). Precision and accuracy of
the myriocin analytical method were previously evaluated
(Campisi et al., 2017) and confirmed in the present study.
The limit of quantification (LOQ) was 0.1 ng/vial, as calculated
by Multiquant software 2.1. The accuracy of the method was
between 80–120% and the CV%<20%. The limit of detection
(LOD) was 0.05 ng/vial, corresponding to a signal-to-noise
ratio greater than 3, according to the ICH Validation of
Analytical Procedures text and methodology. For sphingoli-
pids analysis, six-point calibration curves were built by add-
ing increasing amounts of a standard mixture of 12 ceramide
species in water in the concentration range 0–40 pmol/vial;
the linearity was observed for each ceramide (R2>0.99).
Ocular pharmacokinetics and tolerability
Our experimental protocol complied with the statements of
the Association for Research in Vision and Ophthalmology
(ARVO) for the use of animals in ophthalmic and visual
research. New Zealand (NZ) albino rabbits (weight 2.0–2.5 kg)
were purchased from Envigo s.r.l (San Piero al Natisone,
Udine, Italy). Rabbit can be considered a reliable animal
model for translational ocular pharmacokinetics studies
(Durairaj, 2017). Rabbits were housed in standard conditions
for one week before the experiment (light-controlled room,
controlled temperature 22 ± 1 C and humidity 10–30%).
Rabbits were randomly assigned to two experimental groups
(treated and vehicle): n¼ 10 per experimental group, 2 rab-
bits and 4 retinas per time point. The two experimental
groups of rabbits received ocular topical administration,
30 ml 2 times within 5min of the interval, of Myr-NLC
(NLC1, drug loading 0.68mg/ml) and vehicle (unloaded NLC),
respectively. Rabbits were sacrificed at 30, 60, 120, 180,
240min after ocular topical administration of the myriocin-
NLC and unloaded NLC. Rabbits were sacrificed by intraven-
ous administration of 0.3ml/kg of Tanax# (Intervet, Milano,
Italy), after sedation with an intramuscular administration of
10mg/kg of Zoletil# (Virbac, Milano, Italy). Eyes were
enucleated and ocular tissues (vitreous and retina) were col-
lected. Tissue samples were stored at 80C until quantitative
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analysis of myriocin. Ocular distribution of myriocin was deter-
mined also in the retina of C57BL6J mice after topical adminis-
tration of myriocin-NLC formulation (NLC1, drug loading
0.68mg/ml). In order to increase formulation corneal resi-
dency, three 5ml administrations within 2min of interval were
carried out. The amount of topical administered myriocin was
15mg. C57BL6J mice (n¼ 4) per group were sacrificed 30, 60,
180 and 240min after ocular topical administration of myrio-
cin-NLC formulation; a separate set of animals (n¼ 12) was
used to determine myriocin in control mice (vehicle). Mice
were sacrificed by cervical dislocation; the eye enucleated and
retina collected and stored at 80 C until analysis.
The following pharmacokinetics parameters were deter-
mined in rabbit and mouse eye tissues: peak eye tissue con-
centration (Cmax), and time of peak of eye tissue
concentration (Tmax). The area under the curve (AUC0-240) of
eye tissues was extrapolated from the concentration of myr-
iocin [myriocin] vs. time curves. Ocular safety of unloaded
NLC and Myr-NLC formulations were evaluated by a modified
Draize’s test in a separate set of rabbits (n¼ 6) (Leonardi
et al., 2014; Giannavola et al., 2003). Formulations were topic-
ally administered (30 ll) in the eye every 30min for 6 h (12
treatments). Scores were assigned accordingly to previous
studies, and eyes were examined at 10min and 6 h after
Myr-NLC administration by a slit lamp (4179 T Sbisa,
Florence, Italy). Observations were made by two independent
observers in a masked way.
Statistical analysis
The software GraphPad Prism (version 5.0; GraphPad
Software, San Diego, CA, United States) was used to carry
out statistical analysis and graph design. All data are
expressed as mean values ± standard deviation (SD). The
results were analyzed using one-way ANOVA. Two-way
ANOVA was used for comparison of [myriocin] vs. time
curves. Tukey–Kramer post-hoc multiple comparisons test
was also carried out. Differences between groups were con-
sidered significant given p-values< .05.
Results
Preparation and characterization of the NLC system
NLC were prepared accordingly to an adapted melt-emulsifi-
cation and ultrasonication technique. Lipid matrix and aque-
ous phase’s composition were chosen on the basis of
different experimental tests (data not shown). Chemical con-
tent of formulations is shown in Table 1.
Mean particle size (Z-Ave), polydispersity index (PDI), Zeta
potential (ZP), physical appearance, pH value and physical
stability were determined for unloaded and myriocin-NLC
formulations (Table 2).
Stability studies
Due to the limited stability of myriocin at temperatures
above 0 C, NLC stability was evaluated upon storage in
closed glass vials at 4 C. Mean particle size, PDI, pH and
physical appearance were evaluated for up to 6months after
preparation. We found that both unloaded and Myr- NLC
were physically stable for the tested period of storage
(Table 3). The NLC2 formulation showed a tendency to increase
the mean particle size starting from the third month of storage,
however maintaining the mean particle size below 200nm,
which is suitable for topical ophthalmic administration.
Sterilization
Unloaded NLC formulations were sterilized after preparation;
an aliquot of each sample was sterilized using three syringe
sterile filters. Although, filtration of unloaded NLC0 was quite
easy, the nylon and PTFE 0.2 mm membranes exerted a cer-
tain resistance to filtration of the Myr- NLC formulation. The
PES sterile filter provided an easy filtration of the Myr-NLC
formulation (NLC1), preserving the characteristics of the pre-
filtered NLC batch (mean particle size was 91.33 and
82.34 nm, before and after filtration, respectively).
Ocular distribution of the Myr-NLC formulation (NLC1)
in NZ rabbits and C57BL6J mice
We carried out preliminary comparison of Myr-NLC retinal
distribution with myriocin aqueous suspension (PBS pH 7.4,
[myriocin]¼ 1mg/ml) and a Myr-SLN formulation (see supple-
mental material). Myr-SLN formulation was prepared as previ-
ously reported, without addition of cationic lipid
didecylmethylammonium bromide (Amadio et al., 2016;
Leonardi et al., 2015) (Supplemental material).
NLC1 formulation provided significantly (p< .0001) higher
myriocin retinal availability, after topical ocular administra-
tion, compared to myriocin suspension or Myr-SLN formula-
tion (supplemental material).
We administered 40.8 mg of myriocin (two administration
of 30ml of NLC1, drug loading¼ 0.68mg/ml) to rabbit eye by
topical route, while mice received 10.2 mg myriocin (three
administration of 5 ml of NLC1, drug loading = 0.68mg/ml).
We used two different species for pharmacokinetics study
because rabbits are well known valuable animal model to
assess ocular PK (Durairaj, 2017), while mice were previously
used as genetic animal model of retinitis pigmentosa
Table 1. Composition (%, w/v) of unloaded NLC and Myr-NLC formulations.
Gelucire
44/14
Mygliol
812
Tween
80
Benzalkonium
chloride
Myr theoretical
concentration (mg/ml)
Drug loading
(mg/ml)
% Encapsulation
efficiency
NLC 0 10 5 2.5 0.05 – – –
NLC 1 10 5 2.5 0.05 1 0.68 ± 0.02 68.0
NLC 2 10 5 2.5 0.05 2 1.60 ± 0.003 80.0
Drug loading was determined in three separate samples by means of HPLC-MS/MS.
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(Strettoi et al., 2010). Indeed, we evaluated myriocin retinal
distribution in mice in order to confirm that Myr-NLC formu-
lation is able to guarantee pharmacological levels of drug.
Figure 1 shows myriocin distribution in rabbit vitreous
and retina after topical administration of Myr-NLC (NLC1)
(Table 4). Myriocin levels in rabbit retina were significantly
lower (p< .05) compared to rabbit vitreous levels, 180 and
240min after ocular topical administration of the Myr-NLC
formulation (Figure 1).
Furthermore, Figure 1 shows myriocin distribution in the
retina of Myr-NLC (NLC1) treated mice (Table 4). The myrio-
cin availability in mouse retina was significantly (p< .05)
higher than in rabbits (vitreous and retina; Figure 1 and
Table 4). Myriocin levels detected in mouse retina at 120min
(2.2 104 ± 0.5 104 ng/g), 180min (3.0 105 ± 0.8 105 ng/
g) and 240min (2.0 106± 0.9 106 ng/g) were significantly
(p<.05) higher than retinal drug levels at 30 min and 60 min.
Pharmacokinetic parameters (Tmax, Cmax and AUC0 240)
were extrapolated from [myriocin] vs. time curves (Figure 1)
and reported in Table 4.
Pharmacokinetics parameters of myriocin distribution in
rabbit vitreous are expressed as ng/g (Cmax values) or
ngmin/g (AUC), assuming vitreous density equal to 1
(Struble et al. 2014). Furthermore, we found that unloaded
NLC and Myr-NLC (NLC1) were well tolerated by rabbits. The
scores of the modified Draize’s test were 0, at 10min and 6 h
(data not shown).
Inhibition of de novo sphingolipids biosynthesis
by myriocin
Total ceramides and dihydroceramides levels in the rabbit
retina were determined to evaluate the efficacy of the myrio-
cin delivered with NLC to the back of the eye (Figure 2).
Myr-NLC treatment decreased ceramides and dihydrocera-
mides levels in the rabbit retina, compared to control rabbits
(vehicle). Retinal ceramide levels were found to be signifi-
cantly (p< .05) decreased in the Myr-NLC-treated group com-
pared with the vehicle-treated group, 2312 ± 150 pmol/
mgprot and 5518.5 ± 794.9 pmol/mgprot, respectively
(180min after treatment). Dihydroceramides levels were
found to be significantly (p< .001) decreased in the rabbit
retina 120min (35.9 ± 1.8 pmol/mgprot), 180min
(35.5 ± 5.7 pmol/mgprot) and 240min (47.7 ± 5.1 pmol/
mgprot) after treatment with Myr-NLC, compared to control
rabbits (73.2 ± 6 pmol/mgprot).
Discussion
The eye is characterized by several barriers that limit the
drug bioavailability after topical ocular administration. In
general, only 1–10% of topical administered drugs is
absorbed and about 1% of any instilled drug reaches the
aqueous humor (Bucolo et al., 2012; Macha et al., 2003).
Therefore, drug delivery targeting the retina is a challenging
task, generally by-passed with intravitreal injections.
Currently, anti-VEGF drugs used in clinical practice to treat
age-related macular degeneration are injected intravitreally.
Recently, intravitreal injection of myriocin was also explored
in mice to assess retinal bioavailability by this route (Campisi
Table 2. Characteristics of NLC formulations.
Batch Z-Ave (nm) PDI ZP (mV) Physical appearance pH
NLC 0 86.25 ± 1.530 0.395 ± 0.006 3.81 ± 0.814 Clear 5.73
NLC 1 91.33 ± 3.153 0.658 ± 0.05 1.06 ± 0.179 Lightly milky 5.01
NLC 2 126.7±3.595 0.496 ± 0.002 2.48 ± 0.188 Milky 5.10
Table 3. Stability of NLC and Myr-NLC formulations.
Z-Ave (nm) PDI pH App
Time 0
NLC0 86.25 ± 1.530 0.395 ± 0.006 5.73 Clear
NLC1 91.33 ± 3.153 0.658 ± 0.050 5.01 Lightly milky
NLC2 126.70±3.595 0.496 ± 0.002 5.10 Milky
1 month
NLC0 93.58 ± 0.351 0.316 ± 0.034 5.56 Clear
NLC1 116.51 ± 0.833 0.273 ± 0.007 5.06 Lightly milky
NLC2 134.80 ± 2.06 0.380 ± 0.013 5.09 Milky
3 months
NLC0 102.31 ± 0.521 0.250 ± 0.001 5.55 Clear
NLC1 119.32 ± 1.570 0.244 ± 0.006 5.04 Lightly milky
NLC2 166.22 ± 5.781 0.474 ± 0.074 5.12 Milky
6 months
NLC0 134.90 ± 0.794 0.216 ± 0.022 5.58 Lightly milky
NLC1 122.22 ± 0.195 0.188 ± 0.015 5.20 Lightly milky
NLC2 189.99 ± 4.222 0.313 ± 0.111 5.31 Milky
Figure 1. Myriocin (topically administered as a myriocin-NLC) distribution in
rabbit vitreous and retina. p< .05 mouse retina vs. rabbit vitreous and retina.p< .05 rabbit vitreous vs. rabbit retina.
Table 4. Ocular PK parameters of the myriocin-NLC (NLC1) formulation.
Tissue Tmax (minutes) Cmax (ng/g) AUC0-204 (ngmin /g)
Mouse retina 240 2030061 ± 871475 80556900 ± 9611659†
Rabbit vitreous 240 10996 ± 745 810507 ± 80068
Rabbit retina 180 1646 ± 240 142789 ± 14898
p< .05 AUC0-240 rabbit vitreous vs. rabbit retina; †p< .001 mouse retina vs.
rabbit vitreous/rabbit retina.
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et al., 2017). However, intravitreal injections may damage eye
structures leading to retinal detachment, cataract, hyperemia,
and endophthalmitis.
Intravitreal treatment with myriocin was also investigated
on rd10 mice modeling RP demonstrating a robust reduction
of ceramide retinal levels (Strettoi et al., 2010). The topical
ophthalmic approach was successfully explored (Strettoi
et al., 2010) using solid lipid nanoparticle (SLN) formulation
of myriocin in rd10 mice. Significant rescue effects on photo-
receptor survival and retinal function were found, reflected
in the preservation of the a-wave of ERG in rd10 mice
treated with myriocin (Piano et al., 2013).
Exploitation of nanotechnological approaches led to suc-
cessful drug delivery to the back of the eye in pre-clinical
studies (Altamirano-Vallejo et al., 2018; Papangkorn et al.,
2018; Mahaling et al., 2018; Bucolo et al., 2011); a fruitful
approach, among others, is represented by solid lipid nano-
carriers (SLN) (Battaglia et al., 2016; Leonardi et al., 2015;
Chetoni et al., 2016). In the present study, we exploited the
use of nanostructured lipid carriers (NLC) that represents a
technological evolution of SLN, to deliver myriocin. Main
advantages of NLC are related to a higher physical stability
and drug loading capacity, compared to SLN. NLCs are
obtained by mixing two different lipids, one solid and the
other liquid, at room temperature. This protocol leads to the
formation of a hydrophobic core in the NLC, with structural
in-homogeneities, where drugs can be easily dissolved and
encapsulated in tiny oil compartments. These chemical-phys-
ical properties characterize the high loading capacity and
negligible drug expulsion of NLC (M€uller et al., 2002).
We demonstrated that the Myr-NLC formulation was char-
acterized by high drug loading capacity. Furthermore, the
formulation retains considerable stability at 6months from
formulation preparation. Myr-NLC formulation stability was
evaluated at 4 C, because myriocin is not stable at range
temperature generally used for formulation stability assess-
ment, as reported by International Council for Harmonization
(ICH) guidelines. However, our next goal is to follow up this
preliminary study with a pre-industrial optimization of the
formulation, including (ICH) accelerated stability tests. Both
Myr-NLC and unloaded NLC eye drops were well tolerated
by the rabbit eye. We also characterized, for the first time,
the ocular distribution of the topical ocular Myr-NLC formula-
tion in rabbits and mice. The Myr-NLC formulation efficiently
delivered myriocin to the back of the eye of both treated
mice and rabbits, after single topical ocular administration.
We hypothesize that the Myr-NLC formulation provides a
more robust drug bioavailability to the back of the eye
through preferential conjunctival/scleral drug absorption,
with respect to the trans-corneal route. Moreover, the myrio-
cin-NLC worked as a depot formulation, due to its long cor-
neal residence time, because myriocin (Myr-NLC) reached the
maximum concentration in the back of the eye of rabbits
and mice after 240min, in agreement with previous studies
(Araujo et al., 2012; Schopf et al., 2015). The average weight
of rabbit vitreous is one gram (Struble et al., 2014); therefore,
rabbit vitreous levels of myriocin were 10 mg (vitreous
Cmax 1 g), after administration of the myriocin-NLC (1mg/
ml) formulation. Moreover, the amount of myriocin that
reached the mouse retina was 5.8mg (Cmax) after Myr-NLC
topical ocular treatment. Therefore, myriocin levels both in
rabbit vitreous and mouse retina are in the therapeutic range
previously determined in the rd10 mouse model of RP
(Strettoi et al., 2010). In the present study we demonstrated
that Myr-NLC formulation was able to provide pharmaco-
logical drug levels in rabbit retina. Considering that myriocin
acts as sphingolipid synthesis inhibitor, the remarkable drug
levels in rabbit retina are able to decrease ceramides and
dihydroceramides, as previously demonstrated (Strettoi et al.,
2010). Therefore, our data suggest a potential therapeutic
effect of Myr-NLC to manage retinitis pigmentosa.
Conclusion
Our results demonstrated that the Myr-NLC formulation is
able to deliver effective levels of myriocin to the back of the
eye both in rabbits and mice. Myriocin levels, delivered to
rabbit vitreous and mouse retina, overlapped the pharmaco-
logical effective doses as previously demonstrated in vivo
(Strettoi et al., 2010). The efficacy of Myr-NLC treatment was
also proven by the significant decrease of ceramides and
dihydroceramides levels in Myr-NLC rabbit retina, compared
to vehicle-treated group. In conclusion, these data suggest
that the Myr-NLC ophthalmic formulation is suitable for
pharmaceutical development and warrants further clinical
evaluation for the treatment of retinitis pigmentosa.
Figure 2. Ceramides (A) and dihydroceramides (B) levels in the retina after topical administration of the myriocin-NLC. Ceramide or dihydroceramide range in con-
trol animals is represented by two dotted lines. p< .05 p< .001 Myr-NLC rabbits vs. vehicle-treated group.
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